In evaluating a diabetic male client's response to rosuvastatin, which laboratory value changes would indicate a therapeutic response?

The correct response indicates that a decrease in low-density lipoprotein cholesterol (LDL-C) is a therapeutic response to rosuvastatin. Rosuvastatin is a HMG-CoA reductase inhibitor, commonly known as a statin, which is primarily used to lower cholesterol levels in individuals at risk for cardiovascular disease, including those with diabetes.

In patients with diabetes, managing cholesterol levels is crucial to reduce the risk of cardiovascular complications. Statins work by inhibiting the enzyme responsible for cholesterol synthesis in the liver, thereby decreasing the production of LDL-C. A reduction in LDL-C is associated with a lower risk of atherosclerosis and related cardiovascular events, thus representing an effective therapeutic outcome when monitoring a patient's response to treatment with rosuvastatin.

Changes in other laboratory values, such as an increase in alanine aminotransferase, would indicate potential liver damage, which is a concern with statin therapy and not a desired therapeutic effect. A decrease in high-density lipoprotein cholesterol (HDL-C) would suggest worsening cardiovascular risk, as HDL-C is considered "good" cholesterol that helps remove LDL from the bloodstream. An increase in total cholesterol would also be contrary to the therapeutic goals of treating dyslipidemia with statins